Business context and reporting period
Entity discrepancy: The request identifies Tvardi Therapeutics, Inc., but the supplied filing is for Cara Therapeutics, Inc. This summary reflects the filing text, not Tvardi. The unaudited Form 10-Q covers the quarter ended March 31, 2016; comparative results are for the quarter ended March 31, 2015.
Cara was a clinical-stage biopharmaceutical company developing CR845-based candidates for pain and pruritus. It had no products for sale, and reported revenue was nominal. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 / prior balance date |
|---|---|---|
| Revenue | $7,000 | $489,000 |
| Research and development expense | $8.546 million | $3.385 million |
| General and administrative expense | $2.447 million | $1.822 million |
| Operating loss | $10.986 million | $4.718 million |
| Net loss | $10.692 million | $4.689 million |
| Basic and diluted loss per share | $0.39 | $0.21 |
| Net cash used in operating activities | $9.833 million | $5.241 million |
| Cash and cash equivalents | $7.922 million | $15.101 million at Dec. 31, 2015 |
| Marketable securities | $88.322 million | $91.640 million at Dec. 31, 2015 |
| Total assets | $102.013 million | $110.897 million at Dec. 31, 2015 |
| Current liabilities | $6.089 million | $5.268 million at Dec. 31, 2015 |
| Stockholders’ equity | $94.927 million | $105.044 million at Dec. 31, 2015 |
Unrestricted cash, cash equivalents and marketable securities totaled $96.244 million at March 31, 2016. Restricted cash was $1.469 million. The balance sheet lists no debt balance; it reports accounts payable and accrued expenses and lease obligations. Operating margin is not meaningful given minimal revenue and the operating loss.
Material changes versus the prior comparable period
- Revenue fell 99%, from $489,000 to $7,000; prior-period collaborative revenue was deferred revenue recognized under the Maruishi agreement, while Q1 2016 revenue was clinical compound sales.
- R&D expense increased 153%, chiefly from higher I.V. and oral CR845 trial and manufacturing costs, and increased preclinical work. G&A expense rose 34%.
- Net loss more than doubled, and operating cash use increased by $4.592 million year over year.
- Cash and marketable securities combined declined by $10.497 million from Dec. 31, 2015. Net cash fell $7.179 million during the quarter, partly reflecting investment purchases and an increase in restricted cash.
Outlook, commentary, risks and unusual items
- Management expected March 31 cash and marketable securities to fund planned operations and capital expenditures through the end of Q1 2018, excluding potential collaboration milestones. It cautioned that clinical timing and cost assumptions could prove wrong.
- Management expected R&D spending and operating losses to continue and increase as development advanced. It also stated that additional capital would be needed for all development objectives; financing may be unavailable or dilutive, and programs could be delayed, reduced or terminated.
- The FDA placed the I.V. CR845 postoperative-pain adaptive pivotal trial on clinical hold in February 2016 after four of 90 patients in the highest-dose group experienced transient elevated serum sodium. The patients were asymptomatic and levels normalized within 24 hours. The FDA removed the hold in April 2016, after quarter-end; Cara proposed a revised three-arm trial using lower doses.
- Management planned to initiate an Oral CR845 osteoarthritis Phase 2b trial in the second half of 2016 and a Phase 2/3 adaptive trial of I.V. CR845 for uremic pruritus in Q2 2016. These were forward-looking plans, not reported outcomes.
- A $539,000 acceleration of amortization on Shelton facility leasehold improvements increased Q1 2016 expense; the company expected to stop using that facility in May 2016 and was negotiating with its landlord. Stamford lease commitments totaled $8.268 million; total disclosed operating lease commitments were $9.694 million.
- Unrestricted funds were principally held in cash equivalents and investment-grade marketable securities. Management said a 10% interest-rate change would have an immaterial fair-value effect. No material legal proceedings, off-balance-sheet arrangements, or new risk-factor changes were reported.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is Cara Therapeutics’ 2016 Q1 10-Q, not a Tvardi Therapeutics filing.
- Check subsequent disclosures on the lifted clinical hold, revised I.V. CR845 trial design, enrollment, safety findings and results.
- Verify progress and costs for the planned Oral CR845 osteoarthritis and I.V. CR845 uremic-pruritus trials.
- Assess cash burn against the stated Q1 2018 runway, including whether assumptions changed and whether additional financing was required.
- Review lease negotiations and obligations, and potential milestone receipts under the Maruishi and CKD agreements; such receipts were uncertain.